Cancer Targeted Technology LLC has been awarded the phase I portion ($400,000) of a fast track phase I/II ($2.4 million) Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI) to develop CTT-2274 to treat metastatic prostate cancer.
With two complete response letters in the rearview mirror, Abbvie Inc.’s Vyalev (foscarbidopa/foslevodopa) has been approved by the U.S. FDA for treating Parkinson’s disease. The drug is the first subcutaneous 24-hour infusion of levodopa-based therapy for treating motor fluctuations in adults with advanced disease.
Haihe Biopharma Co. Ltd. has published work on the discovery of novel ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) inhibitors being developed for the treatment of cancer.
Cycloicaritin (CICT) is a bioactive natural flavonoid extracted from Epimedium species with anti-inflammatory, antimicrobial or antiproliferative effects but with low bioavailability.
Immunodesigners Co. Ltd. has discovered optical isomers of 2'-fluoro-6'-methylene carbocyclic adenosine monophosphate prodrug reported to be useful for the treatment of chronic hepatitis B.
Previous preclinical studies of the prodrug of cidofovir, NPP-669, have shown its oral bioavailability, excellent metabolic and pharmacokinetic parameters, as well as its broad-range activity against dsDNA viruses in vitro.
Development and optimization of novel oral selective hematopoietic progenitor kinase 1 (HPK1) inhibitors for immuno-oncology (IO) treatment were reported by scientists from Astrazeneca plc in two presentations during the ACS meeting this week.
Researchers from Baylor University and collaborators have described the synthesis and evaluation of a series of 6-aryl-3-aroyl-indole analogues acting as tubulin polymerization inhibitors aimed to be used as anticancer agents. Inhibitors of tubulin polymerization are promising antiproliferative agents and their interaction with the colchicine site is linked to its activity as vascular disrupting agents (VDAs).
